Epalnest M Tablet contains Epalrestat 150 mg and Methylcobalamin 1500 mcg, a specialized combination formulated to support nerve health and help manage diabetic neuropathy. The medicine is designed to address nerve damage associated with prolonged elevated blood glucose levels and provides comprehensive support for nerve function and repair. It is prescribed under medical supervision as part of an integrated approach to neuropathy management and diabetic care.
Epalrestat acts as an aldose reductase inhibitor that helps reduce the accumulation of sorbitol within nerve tissues, a process associated with diabetic nerve damage. By targeting this pathway, it helps protect nerves from further injury and supports healthier nerve function. Methylcobalamin, an active form of Vitamin B12, plays an essential role in nerve regeneration, myelin sheath maintenance, and normal neurological function. Together, these ingredients provide synergistic support for nerve protection and recovery.
The tablet is commonly prescribed for diabetic neuropathy and related nerve disorders characterized by symptoms such as numbness, tingling, burning sensations, pain, and reduced sensation in the extremities. Regular use as directed may help improve nerve health, reduce neuropathic symptoms, and support better quality of life in patients with diabetes-related nerve complications. The treatment plan should be followed in conjunction with appropriate blood sugar management and lifestyle modifications.
With the rising prevalence of diabetes and increasing awareness regarding diabetic complications, Epalnest M Tablet maintains strong demand in the neurology and diabetic care segments. Its clinically relevant combination, physician confidence, and growing need for effective neuropathy management solutions contribute to sustained market potential. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the neuro-care pharmaceutical sector.